.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Check market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

OFEV Drug Profile

« Back to Dashboard
Ofev is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from one supplier. There are three patents protecting this drug.

This drug has one hundred and two patent family members in forty-two countries.

The generic ingredient in OFEV is nintedanib esylate. One supplier is listed for this compound. Additional details are available on the nintedanib esylate profile page.

Summary for Tradename: OFEV

Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list53
Clinical Trials: see list4
Patent Applications: see list64
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:OFEV at DailyMed

Pharmacology for Tradename: OFEV

Drug ClassKinase Inhibitor
Mechanism of ActionProtein Kinase Inhibitors
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Boehringer Ingelheim
OFEV
nintedanib esylate
CAPSULE;ORAL205832-001Oct 15, 2014RXYesNo7,989,474► subscribe ► subscribe
Boehringer Ingelheim
OFEV
nintedanib esylate
CAPSULE;ORAL205832-002Oct 15, 2014RXYesYes7,119,093► subscribeYY ► subscribe
Boehringer Ingelheim
OFEV
nintedanib esylate
CAPSULE;ORAL205832-001Oct 15, 2014RXYesNo► subscribe► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: OFEV

Country Document Number Estimated Expiration
Japan4021664► subscribe
Japan5039279► subscribe
European Patent Office1527047► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: OFEV

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90015-2Sweden► subscribePRODUCT NAME: NINTEDANIB, THE TAUTOMERS AND THE SALTS THEREOF, IN PARTICULAR NINTEDANIB AND PHYSIOLOGICALLY ACCEPTABLE SALTS THEREOF, SPECIFICALLY NINTEDANIB ESILATE; REG. NO/DATE: EU/1/14/954 20141121
681Luxembourg► subscribePRODUCT NAME: INDOLINONES SUBSTITUEES EN POSITION 6, LEUR PREPARATION ET LEUR UTILISATION EN TANT QUE MEDICAMENTS; FIRST REGISTRATION: 20141121
C0024France► subscribePRODUCT NAME: NINTEDANIB,SES TAUTOMERES ET SES SELS,EN PARTICULIER LES SELS PHYSIOLOGIQUEMENT ACCEPTABLES DE NINTEDANIB ET PLUS PARTICULIEREMENT L'ESILATE; REGISTRATION NO/DATE: EU/1/14/954 20141125
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc